Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
InteractionPODN interactions

IL17RA DCAF8

4.95e-0518122int:PODN
InteractionZNF558 interactions

CLK2 HEXIM2

1.05e-0426122int:ZNF558
CoexpressionWIERENGA_STAT5A_TARGETS_DN

GP6 IL17RA HEXIM2

8.23e-05193123M2213
CoexpressionGSE2197_IMMUNOSUPPRESSIVE_DNA_VS_UNTREATEDIN_DC_DN

RINL NODAL PEX10

9.02e-05199123M4390
CoexpressionGSE16522_ANTI_CD3CD28_STIM_VS_UNSTIM_MEMORY_CD8_TCELL_DN

RINL DGKZ DCAF8

9.15e-05200123M3664
ToppCellTCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma|TCGA-Liver / Sample_Type by Project: Shred V9

CLK2 B4GALT7 ZNF219

2.39e-052001339cff8be6e566f342fc8b45e93106d033b14759ee
ToppCellTCGA-Liver-Primary_Tumor|TCGA-Liver / Sample_Type by Project: Shred V9

CLK2 B4GALT7 ZNF219

2.39e-05200133b667168081393433597f6ca8baeddba1d1906d40
ToppCellCOVID-19-Mast_cells-Dendritic_cells|COVID-19 / group, cell type (main and fine annotations)

RINL GP6

7.44e-041411320fc06c2325249aa4ae65c0ace1ec3f953372f2e4
ToppCellControl-Lymphocytic_NKT-T_cells-iNKT-MAIT|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

GP6 B4GALT7

8.52e-041511327e5e35ce601ca3d3722063566e89664909171b8d
ToppCellTCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-3|TCGA-Colorectal / Sample_Type by Project: Shred V9

PEX10 B4GALT7

1.00e-03164132201aee6387e69f918d87fa87d9b5b2ab3b305f61
ToppCellfacs-Brain_Non-Myeloid-Cortex_-18m-Lymphocytic-mature_NK_T_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RINL GP6

1.03e-03166132410843ad44f9b22d5476119ac0d7c9168e17ac4b
ToppCelldroplet-Kidney-nan-24m-Myeloid-nan|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GP6 IL17RA

1.04e-031671322ee1660be117e20f24557522345572d11cbee813
ToppCellcellseq-Immune-Hematopoietic-Megakaryocyte/Platelet|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

GP6 HEXIM2

1.10e-03172132eb2915165cab2660511e4b70c3a6d3ab2f770809
ToppCellcellseq-Immune-Hematopoietic-Megakaryocyte/Platelet-Megakaryocyte/Platelet|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

GP6 HEXIM2

1.10e-03172132d0c3fb48c61762dcefca858cf13c9da8eb6d0f5e
ToppCell10x3'2.3-week_14-16-Hematopoietic-HSC/MPP_and_pro-CMP|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

MIR1915HG DCAF8

1.10e-03172132f18d9f061df3da96e389616abd5edfc269d3adeb
ToppCellwk_15-18-Hematologic-Myeloid-Promyelocyte-like|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

DGKZ IL17RA

1.13e-031741321c0c04c37bfdbdb47bda57784734e0c5f1e8ed87
ToppCellPBMC-Convalescent-Hematopoietic-Platelet-Platelet|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GP6 HEXIM2

1.18e-03178132a2a8fc14f492a4695e6991a357b6626145f1bf7f
ToppCellPBMC-Convalescent-Hematopoietic-Platelet|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GP6 HEXIM2

1.18e-03178132f5d83ad082e31d5601890d245b9fb4f9ef6a062b
ToppCellfacs-Liver-Liver_non-hepato/SCs_st-18m-Lymphocytic-mature_NK_T_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RINL GP6

1.18e-0317813208c6794eb21c062c7e6c2e297e8c14dcf0e12774
ToppCellPBMC-Convalescent-Hematopoietic-Platelet|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.19e-03179132906a5ebbbac660b6fd498ced09d0ada40a3e64af
ToppCellPBMC-Convalescent-Hematopoietic-Platelet-Platelet|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.19e-03179132510927794bbd21814eba75286e0801eb1fd2e8a6
ToppCellPBMC-Convalescent-Hematopoietic|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)

GP6 HEXIM2

1.19e-031791323b1616e974ea7792ff5c37da3b0281f28edfbb56
ToppCellPBMC-Convalescent-Hematopoietic|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.19e-0317913235271a4396a533f6d960ce55d171a32d9d2fd1a4
ToppCell368C-Lymphocytic-ILC-ILC-2|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

B4GALT7 ZNF219

1.21e-03180132eb5a57604c7f2ad256c300085dbf5069d0ae1ad0
ToppCellCOVID-19_Convalescent-Hematopoietic_Mega-Platelet|COVID-19_Convalescent / Disease group, lineage and cell class

GP6 HEXIM2

1.21e-03180132deed53167504c91220b35a63366ed7d8f02a5254
ToppCellPBMC-Convalescent-Hematopoietic-Platelet-Platelet-plt_1|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GP6 HEXIM2

1.21e-031801323c605d6adb4199963532f3639f2c768f7e575152
ToppCellCOVID-19_Convalescent-Hematopoietic_Mega|COVID-19_Convalescent / Disease group, lineage and cell class

GP6 HEXIM2

1.21e-0318013217323d382ae322e388e230fdad13e3464ea73e8e
ToppCellmegakaryocytic-Platelet|World / Lineage and Cell class

GP6 HEXIM2

1.21e-03180132c007c3e63c2bb35ed34327dd8863899b5db93115
ToppCellPBMC-Convalescent-Hematopoietic-Platelet-Platelet-plt_1|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.21e-031801323d52ca0568f9c0d6359b302ff5ff41b075f78597
ToppCell368C-Lymphocytic-ILC|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

B4GALT7 ZNF219

1.21e-03180132ddba4dc3bbcfe4e4a22400be73bbc62d3ff27d3c
ToppCellPBMC-Convalescent-Hematopoietic-Platelet-Platelet-plt_4|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.27e-03185132709236097cbfc254796fcc69b5f5178b73dad9bd
ToppCellPBMC-Convalescent-Hematopoietic-Platelet-Platelet-plt_4|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GP6 HEXIM2

1.27e-03185132af078a6c4a3e0b54b7d8ab7b30dcd06053ebfd28
ToppCellPBMC-Control-Hematopoietic-Platelet-Platelet-plt_1|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GP6 HEXIM2

1.29e-0318613213a9ddcf93b0c4319ab9d484af5e2056e9754caa
ToppCellPBMC-Control-Hematopoietic-Platelet-Platelet-plt_1|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.29e-03186132107bc473f5e57238390f8e0ab9f7263a8f93948c
ToppCellHealthy_donor-Platelet|Healthy_donor / disease group, cell group and cell class (v2)

GP6 HEXIM2

1.30e-031871329040ffa5c23913b9dc0205fa6227223c2a2847ae
ToppCellremission-Platelet|World / disease stage, cell group and cell class

GP6 HEXIM2

1.31e-03188132fa69f20ef6b8ce620ba342f0984d40ddf259bc3f
ToppCellmild_COVID-19-Platelet|World / disease group, cell group and cell class (v2)

GP6 HEXIM2

1.33e-03189132038ec3c266b89416bb5b774ba522d916394961da
ToppCell367C-Lymphocytic-NK_cells-NK_cell_B|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

ZNF219 HEXIM2

1.33e-03189132160963355256f7c0f2138da80c90de478f5a9fe8
ToppCellHealthy-Platelet|World / disease group, cell group and cell class

GP6 HEXIM2

1.33e-03189132c3d8e3682cb489bca887039cbea6c4cfc264de2f
ToppCellPBMC-Mild-Hematopoietic-Platelet-Platelet|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

GP6 HEXIM2

1.34e-03190132a1f8757dc719ed030f67d65735358a8d7a407bad
ToppCellPBMC-Mild-Hematopoietic-Platelet|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.34e-03190132726aeb280ea911f3551b18e388c4f7580ae2ea74
ToppCellPBMC-Mild-Hematopoietic-Platelet|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

GP6 HEXIM2

1.34e-03190132c4f55f5a0c42aeb571791925ea80e02fac320608
ToppCellCOVID-19_Moderate-Platelet|COVID-19_Moderate / disease group, cell group and cell class

GP6 HEXIM2

1.34e-031901323bf4ab3fd3a391da98a83e2aac0881a0e5c8f8b0
ToppCellCOVID-19_Moderate-Platelet|World / disease group, cell group and cell class

GP6 HEXIM2

1.34e-031901326e4f4af5ba185bb022753881a26a269a544bb59b
ToppCellPBMC-Mild-Hematopoietic-Platelet-Platelet|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.34e-0319013250ea3ff7ba1ca335b4e4538fae5f9b74b1fc10f7
ToppCellPBMC-Mild-Hematopoietic-Platelet-Platelet-plt_1|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.34e-03190132b719061be370ffc293854f1f6e526bf33cd2f442
ToppCellPBMC-Mild-Hematopoietic-Platelet-Platelet-plt_1|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GP6 HEXIM2

1.34e-03190132427038bae9c7b3a9441c8d59ace69da74e9d37bf
ToppCellHealthy_donor-Platelet|World / disease group, cell group and cell class (v2)

GP6 HEXIM2

1.36e-03191132defae87313d6345e3f451250fd66fe8831bb441c
ToppCellCOVID-19_Mild-Hematopoietic_Mega-Platelet|COVID-19_Mild / Disease group, lineage and cell class

GP6 HEXIM2

1.36e-031911326b3cfc670f69ed3e757cbf7498943e549e31326e
ToppCellPBMC-Severe-Hematopoietic-Platelet-Platelet-plt_1|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GP6 HEXIM2

1.36e-031911327da172553ed6df4a0c34ecd55665a9598b5071a5
ToppCellPBMC-Severe-Hematopoietic-Platelet-Platelet-plt_1|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GP6 HEXIM2

1.36e-031911321a1bf85bc77bf093a0ac2cb9eabaeac820a7b93e
ToppCellmild_COVID-19-Platelet|mild_COVID-19 / disease group, cell group and cell class (v2)

GP6 HEXIM2

1.36e-03191132968e2d48969884dd21b8a87f199af94a7410b0dd
ToppCellmild_COVID-19_(asymptomatic)-Platelet|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)

GP6 HEXIM2

1.38e-031931329b97a7e9b5c1cc5db353070af0b9c5059714724b
ToppCell10x5'-blood|World / Manually curated celltypes from each tissue

GP6 IL17RA

1.38e-03193132359d4242a7e5e51a3eaf6fe51bc1c653a402b054
ToppCellfacs-Thymus-nan-3m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DGKZ IL17RA

1.40e-0319413266c056232ac216780acf4cc8ea325bd8ed1909c9
ToppCellfacs-Thymus-nan-3m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DGKZ IL17RA

1.40e-03194132f1661f9f2439fca5c1012c693b0744c4e3b90a9b
ToppCellfacs-Thymus-nan|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DGKZ IL17RA

1.40e-03194132cda1b197efb199330ea7ab25a7cee22cae22589d
ToppCellwk_15-18-Hematologic-Myeloid-Promonocyte-like|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

DGKZ IL17RA

1.41e-0319513237b4f635b71734c6e0bc808a739af4bbe6bb47f6
ToppCell10x3'2.3-week_12-13-Myeloid_monocytic|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.46e-03198132de8417b536448312d6c82e424b45a610f8a455d6
ToppCell10x3'2.3-week_12-13-Myeloid_monocytic-monocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.46e-0319813264bb74e2aadfc68937464ddf0a435d7230004dcb
ToppCell10x3'2.3-week_14-16-Myeloid_monocytic-monocyte-promonocyte|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.46e-03198132ff634a17195d06a8614ed1c6564937d10ca5c00d
ToppCell10x3'2.3-week_12-13-Myeloid_monocytic-monocyte-promonocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.46e-03198132b0747b0607d67a480a0a563b775007975c3eab32
ToppCell10x3'2.3-week_14-16-Myeloid_monocytic-monocyte|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.46e-03198132eae8c29d68cc94bfbd15e487ad855639c2a4fcc9
ToppCell10x3'2.3-week_14-16-Myeloid_monocytic|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.46e-031981322f94fb4a1719d5adddb4fd3dfaf099ee2b642011
ToppCell10x5'v1-week_17-19-Myeloid_monocytic-monocyte-promonocyte|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-03199132b725a9c9bdc307641958a8f3ab2f6af9e7a0163d
ToppCell10x5'v1-week_14-16-Myeloid_monocytic-monocyte-promonocyte|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-03199132f7661a386224682e1d79cc9949204d05c0dfe324
ToppCell10x5'v1-week_14-16-Myeloid_monocytic-monocyte|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-031991327f5d47e49776114d9f4a42017fead9eeb415a94c
ToppCell10x5'v1-week_12-13-Myeloid_monocytic-monocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-031991323a50ca40f6147fac7ce0d201717781d3939bbebe
ToppCell10x5'v1-week_17-19-Myeloid_monocytic|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-03199132aa30a57c0907d012942e7babdbff6ea4d01d7798
ToppCell10x5'v1-week_12-13-Myeloid_monocytic|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-031991323d6fa56da7b6bc1e045f80ddfe460d2d5715567e
ToppCellPBMC-Control-cDC_0|Control / Compartment, Disease Groups and Clusters

DGKZ IL17RA

1.47e-03199132ebf03979ef56e978d72db475bb635b43b9cbe402
ToppCell10x5'v1-week_12-13-Myeloid_monocytic-monocyte-promonocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-03199132afa709fe1cf715d85c7fb07b42065890b9010265
ToppCell10x5'v1-week_14-16-Myeloid_monocytic|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-031991325caaf66b6cddcc8f0d0aee3c9ba80d02075e87e5
ToppCell10x5'v1-week_17-19-Myeloid_monocytic-monocyte|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.47e-031991327e5a56bb2ac441a8fa4ad0b928f9c0c82d128190
ToppCellCOVID-19-COVID-19_Mild-Others|COVID-19_Mild / Disease, condition lineage and cell class

GP6 HEXIM2

1.48e-03200132ecf94be4bb961ec343471547f2ea327bc6f709f4
ToppCellFetal_brain-organoid_Tanaka_cellReport-GW12-Macroglial-Astrocyte|GW12 / Sample Type, Dataset, Time_group, and Cell type.

GP6 ZNF219

1.48e-03200132b9bd6c4381c92bfc1bfff9aa778a62a41d08f1ef
ToppCell10x5'v1-week_17-19-Myeloid_monocytic-monocyte-CD14_monocyte|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.48e-0320013207197f95282ee607db17b92fea1376051e65fc50
ToppCellCOVID-19-COVID-19_Convalescent-Others|COVID-19_Convalescent / Disease, condition lineage and cell class

GP6 HEXIM2

1.48e-03200132d09225512a95bc335056275204d1455b8306e7fc
ToppCellCOVID-19-COVID-19_Convalescent-Others-Platelet|COVID-19_Convalescent / Disease, condition lineage and cell class

GP6 HEXIM2

1.48e-032001325547e7173293fce403706f69331ce3976da73a32
ToppCellTCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma|TCGA-Liver / Sample_Type by Project: Shred V9

B4GALT7 ZNF219

1.48e-03200132bc7aba2885ca1093fcd884807b497700dae4835e
ToppCellCOVID-19-COVID-19_Mild-Others-Platelet|COVID-19_Mild / Disease, condition lineage and cell class

GP6 HEXIM2

1.48e-03200132bf5e7a36d6ed44a30f906702b40ace3ecd423398
ToppCell10x3'2.3-week_12-13-Myeloid_monocytic-monocyte-CD14_monocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

DGKZ IL17RA

1.48e-032001324984d27b3768be3b8fca3391cd2b7ab1749e2913
DrugPenbutolol sulfate [38363-32-5]; Down 200; 5.8uM; MCF7; HT_HG-U133A

B4GALT7 IL17RA ZNF219 DCAF8

3.66e-061971347476_DN
DrugLoracarbef [121961-22-6]; Down 200; 10.8uM; MCF7; HT_HG-U133A

PEX10 B4GALT7 IL17RA DCAF8

3.73e-061981345492_DN
Drug2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A

PEX10 B4GALT7 DCAF8

1.59e-041921335206_DN
DrugIsradipine [75695-93-1]; Down 200; 10.8uM; PC3; HT_HG-U133A

PEX10 B4GALT7 IL17RA

1.64e-041941336347_DN
DrugKhellin [82-02-0]; Down 200; 15.4uM; HL60; HG-U133A

PEX10 B4GALT7 DCAF8

1.66e-041951332004_DN
DrugApomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; MCF7; HT_HG-U133A

B4GALT7 IL17RA ZNF219

1.66e-041951335283_UP
Drug5253409; Down 200; 17uM; MCF7; HT_HG-U133A_EA

PEX10 IL17RA DCAF8

1.69e-04196133844_DN
DrugBacitracin [1405-87-4]; Down 200; 2.8uM; MCF7; HT_HG-U133A

B4GALT7 IL17RA DCAF8

1.69e-041961337448_DN
DrugPyrilamine maleate [59-33-6]; Down 200; 10uM; MCF7; HT_HG-U133A

PEX10 IL17RA DCAF8

1.71e-041971337223_DN
DrugLY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A

CLK2 ZNF219 DCAF8

1.71e-041971331641_DN
DrugCytisine (-) [485-35-8]; Down 200; 21uM; MCF7; HT_HG-U133A

PEX10 IL17RA DCAF8

1.71e-041971336217_DN
DrugMephenytoin [50-12-4]; Down 200; 18.4uM; MCF7; HT_HG-U133A

PEX10 IL17RA ZNF219

1.71e-041971336275_DN
Drugrosiglitazone; Down 200; 10uM; MCF7; HT_HG-U133A_EA

PEX10 B4GALT7 DCAF8

1.71e-041971331071_DN
DrugBepridil hydrochloride [74764-40-2]; Down 200; 10uM; MCF7; HT_HG-U133A

PEX10 B4GALT7 DCAF8

1.71e-041971332629_DN
DrugDienestrol [84-17-3]; Down 200; 15uM; MCF7; HT_HG-U133A

PEX10 B4GALT7 DCAF8

1.74e-041981336208_DN
DrugIdazoxan hydrochloride [79944-56-2]; Down 200; 16.6uM; MCF7; HT_HG-U133A

PEX10 IL17RA DCAF8

1.76e-041991336465_DN
DrugAllantoin [97-59-6]; Down 200; 25.2uM; MCF7; HT_HG-U133A

PEX10 IL17RA DCAF8

1.79e-042001335471_DN

Protein segments in the cluster

PeptideGeneStartEntry
HYRSRKHKRRRSRSW

CLK2

21

P49760
RKEWRLHRGLSHRRA

PEX10

246

O60683
AAARTRLLRWHHRVP

MIR1915HG

61

Q5T4H9
FLSKLRHHHRRWRFT

IL17RA

131

Q96F46
RHLHDPAWRKRDQKR

B4GALT7

256

Q9UBV7
WHSRRKRLRHRGRAV

GP6

291

Q9HCN6
WFLMHHLRQRRHHRR

DCAF8

546

Q5TAQ9
HLRQRRHHRRWREPG

DCAF8

551

Q5TAQ9
EPTFVRHHWVHRRRQ

DGKZ

166

Q13574
RHHWVHRRRQDGKCR

DGKZ

171

Q13574
WGKRHRRHHLPDRSQ

NODAL

231

Q96S42
HRRRPSKRKRHWRPY

HEXIM2

91

Q96MH2
WHRRRTLHRKDHPRA

RINL

531

Q6ZS11
PKRGRHAWTHRLRER

SSX8P

156

Q7RTT4
AERERHLHILHRPWK

ZNF219

176

Q9P2Y4